RenaMed Biologics, Inc.

Bio-replacement therapies, mainly for renal failures

RenaMed Biologics, Inc. (previously known as Nephros Therapeutics) is a clinical stage cellular therapy company that deals with the development and commercialisation of human cell replacement systems.

Gregory D. Phelps, President and CEO
Richard A. Andrews, Chief Business Officer
Mark Fitzpatrick, CFO
Bradley J. Maroni, MD, CMO
H. David Humes, MD, Founder and CSO

Gregory D. Phelps, Chairman
Marc D. Beer
Richard Epstein
Norman A. Jacobs
James P. Sherblom
William White, III

Glenn M. Chertow, MD
Ravindra L Mehta, MD

6 Court Drive
Lincoln, RI 02865
USA
Phone: +1-401-333-3789
Fax: +1-401-333-3774

RenaMed’s core technology is used for the isolation and expansion of ex vivo human progenitor cells. This technology includes methods for growing specific renal stem cell isolates in monolayers on hollow fibres using a proprietary system called Renal Assist Device (RAD). The hollow fibres support the cellular system, allowing the transport of essential cell products and nutrients, and preventing the cells from entering the circulatory system.

The company has completed its Phase I/II FDA trials on the Renal Assist Device (RAD) which is intended to treat acute renal failure (ARF).